Jul 14, 2010
By:
George Koroneos, Online Content & News Editor
Vivus's weight-loss drug Qnexa is heading into an FDA review with the backing of generally positive study data. Will FDA give the thumbs up? Depends on how severe it thinks the side effects are.
|
Apr 1, 2010
By:
George Koroneos, Online Content & News Editor
IMS Health reports a nice increase in prescription sales from 2008 to 2009, even with a recession in full swing. That said, numbers are still well below the historic sales of a few years back, and it's anyone's guess if they will reach that high again.
|
Mar 10, 2010
By:
George Koroneos, Online Content & News Editor
Monday was a gloomy day for industry as two separate drug trials went belly up. AstraZeca's Recentin proved that it wasn't up-to-snuff compared with Avastin, and the Roche/Biogen Idec arthritis collaboration treatment, ocrelizumab, may have led to fatalities.
|
Mar 3, 2010
By:
George Koroneos, Online Content & News Editor
The Indian generic firm Ranbaxy was dealt another blow this week as its version of the enlarged prostate drug Flomax was denied approval in the US just as it was about to go to market.
|
Feb 3, 2010
By:
George Koroneos, Online Content & News Editor
Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast.
|
Jan 27, 2010
By:
George Koroneos, Online Content & News Editor
All eyes are on PatientsLikeMe's new epilepsy site. The social network is backed by UCB, but the pharma firm is taking a hands-off approach. Is this the future of pharma social media?
|
Jan 20, 2010
By:
George Koroneos, Online Content & News Editor
GlaxoSmithKline announced that it would open up its library of prospective molecules and investigational vaccines. This move gives researchers free access to study experimental treatments for illnesses that plague the world's poorest countries.
|
Jan 13, 2010
By:
George Koroneos, Online Content & News Editor
The push for government transparency continues with Phase I of FDA's plan to expose the inner workings of that secretive cabal known as the Food and Drug Association. First up, fancy new FAQs.
|
Jan 13, 2010
By:
George Koroneos, Online Content & News Editor
At time when people can't even get a 3 percent cost-of-living increase, how can pharma justify price hikes pushing 500 percent (in some categories). A new study by the government's General Accountability Office examines why drug products took a massive price leap in recent years.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
